DDInter228 DDInter875
Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post-treatment. The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodg
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Brentuximab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pitavastatin
Brentuximab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis A Vaccine
Brentuximab vedotin {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Brentuximab vedotin {u} may lead to a major life threatening interaction when taken with {v} Samarium (153Sm) lexidronam
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Brentuximab vedotin may lead to a major life threatening interaction when taken with Teriflunomide
Brentuximab vedotin may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam